Sanofi Moves Closer to Multiple Sclerosis Drug Approval

Sanofi (NYSE: SNY  ) announced today that the Food and Drug Administration accepted its supplemental Biologics License Application requesting permission to market Lemtrada for the treatment of relapsing multiple sclerosis.

The active ingredient in Lemtrada was originally approved as Campath to treat leukemia, but Sanofi pulled Campath off the market, with some speculating that this was because the difference between the leukemia dose and the multiple sclerosis dose would have made the drug extremely cheap for the multiple sclerosis patients.

The marketing application is based on two phase 3 studies comparing Lemtrada to Pfizer (NYSE: PFE  ) and Merck KGaA's Rebif. One study compared the drugs in patients new to treatment while the other tested patients who had relapsed while on a prior therapy.

Sanofi expects a decision from the FDA in the second half of the year. A decision from the Committee for Medicinal Products for Human Use in the EU is expected in the second quarter.

Separately, Sanofi gave investors an update on the launch of its recently approved oral multiple sclerosis drug, Aubagio. More than 80% of multiple sclerosis specialists in the U.S. have prescribed Aubagio, according to the company, and four out of five patients are switching from another medication with more than half of those coming from Teva Pharmaceutical's Copaxone or Biogen Idec's Avonex, which both have to be injected.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2219051, ~/Articles/ArticleHandler.aspx, 9/1/2014 11:11:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...